LUPIN-TRAMADOL/ACET TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

TRAMADOL HYDROCHLORIDE; ACETAMINOPHEN

থেকে পাওয়া:

LUPIN PHARMA CANADA LIMITED

এটিসি কোড:

N02AJ13

INN (আন্তর্জাতিক নাম):

TRAMADOL AND PARACETAMOL

ডোজ:

37.50MG; 325.00MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

TRAMADOL HYDROCHLORIDE 37.50MG; ACETAMINOPHEN 325.00MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

10/60

প্রেসক্রিপশন টাইপ:

Narcotic (CDSA I)

থেরাপিউটিক এলাকা:

OPIATE AGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0250601001; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2021-11-05

পণ্য বৈশিষ্ট্য

_ _
_ _
_ _
_Page 1 of 64_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
LUPIN-TRAMADOL/ACET
House Standard
acetaminophen and tramadol hydrochloride tablets
37.5 mg tramadol hydrochloride/325 mg acetaminophen
Centrally Acting Analgesic
Lupin Pharma Canada Limited
1155 René-Lévesque West Blvd.
Suite 2500
Montreal QC
H3B 2K4
Date of Revision:
July 19, 2018
SUBMISSION CONTROL NO: 216388
_ _
_ _
_ _
_Page 2 of 64_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE REACTIONS
.....................................................................................................
17
DRUG INTERACTIONS
.....................................................................................................
21
DOSAGE AND ADMINISTRATION
.................................................................................
24
OVERDOSAGE
...................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 28
STORAGE AND STABILITY
.............................................................................................
35
SPECIAL HANDLING INSTRUCTIONS
..........................................................................
35
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 35
PART II: SCIENTIFIC INFORMATION
...............................................................................
37
PHARMACEUTICAL INFORMA